Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 9/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 8/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 5/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 4/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.73 |
| ▸ | CFTR | P13569 | 3/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridopyridazinone SCHEMBL31427010 | 1.00 | PDE4A (1.00) | PDE4APDE4DPDE4CPDE4BPDE3B | |
| Pyridopyridazinone SCHEMBL31427009 | 1.00 | PDE4A (1.00) | PDE4APDE4DPDE4CPDE4BPDE3B | |
| Pyridopyridazinone SCHEMBL7367220 | 0.99 | PDE4A (0.98) | PDE4APDE4DPDE4CPDE4BPDE3B | |
| SCHEMBL7363642 | 0.93 | PDE4A (0.87) | PDE4APDE4DPDE4CPDE4BPDE3B | |
| SCHEMBL7364068 | 0.92 | PDE4A (0.85) | PDE4APDE4DPDE4CPDE4BPDE3B | |
| SCHEMBL7366130 | 0.90 | PDE4A (0.82) | PDE4APDE4DPDE4CPDE4BPDE3B | |
| SCHEMBL7362628 | 0.89 | PDE4A (0.81) | PDE4APDE4DPDE4CPDE4BPDE3B | |
| SCHEMBL7364816 | 0.87 | PDE4A (0.76) | PDE4APDE4DPDE4CPDE4BPDE3B | |
| SCHEMBL8697092 | 0.86 | PDE4A (0.75) | PDE4APDE4DPDE4CPDE4BPDE3B | |
| SCHEMBL7370218 | 0.86 | PDE4A (0.75) | PDE4APDE4DPDE4CPDE4BPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1418896-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | Vivus, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| WO-2003000343-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | VIVUS, INC. (US) | 2003-01-03 | — | — | WO | claimed |
| EP-1418896-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | Vivus, Inc. (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20040014761-A1 | Treatment of female sexual dysfunction with phosphodiesterase inhibitors | VIVUS, INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2003000343-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | VIVUS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| US-6403597-B1 | PRETREATMENT SEXUAL INTERCOURSE | VIVUS, INC. | 2002-06-11 | — | — | US | disclosed |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | VIVUS, INC. | 2002-03-28 | — | — | US | disclosed |
| EP-0612321-B1 | PYRIDO PYRIDAZINONE AND PYRIDAZINTHIONE COMPOUNDS WITH PDE IV INHIBITING ACTIVITY | SYNTEX INC (US) | 1999-08-25 | — | — | EP | disclosed |
| US-5716954-A | ANTIINFLAMMATORY AGENT, ANTIHISTAMINES, IMMUNOSUPPRESSION,AUTOIMMUNE DISEASES | SYNTEX U.S.A. INC. (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0612321-A1 | PYRIDO PYRIDAZINONE AND PYRIDAZINTHIONE COMPOUNDS WITH PDE IV INHIBITING ACTIVITY | SYNTEX (U.S.A.) INC. (US) | 1994-08-31 | — | — | EP | disclosed |
| WO-1993007146-A1 | BENZO AND PYRIDO PYRIDAZINONE AND PYRIDAZINTHIONE COMPOUNDS WITH PDE IV INHIBITING ACTIVITY | SYNTEX (U.S.A.) INC. (US) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | PDE5A, PDE3B, PDE3A | PDE4A 5/4885PDE4D 6/4885PDE4C 7/4885 |
| US-20040014761-A1 | Treatment of female sexual dysfunction with phosphodiesterase inhibitors | PDE3A, PDE3B, PDE12 | PDE4A 6/4885PDE4D 11/4885PDE4C 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.